Xintela publishes efficacy results with EQSTEM from preclinical equine OA study

The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. Xintela has previously published that integrin α10β1-selected stem cells from […]

Västra Hamnen Corporate Finance initiates coverage of Xintela

Xintela has entered into an agreement regarding commissioned equity research with Västra Hamnen Corporate Finance AB. The analysis includes a review of the company, its products, markets and competitors, as well as a financial scenario that forms the basis for an overall assessment of the company’s justified market capitalisation. Västra Hamnen will monitor the development […]

Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)

Xintela today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Xintela has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik […]

Xintela AB Interim Report January – September 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before tax totalled TSEK 11,953 (loss: 14,456).Loss per share was SEK 0.02 (loss: 0.11). First nine month 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]

Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study has now assessed all three dose levels safe at the planned three-month follow-up. XSTEM, which consists of allogeneic (donated) integrin […]

Xintela AB Interim Report January – June 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 18,401 (loss: 18,942).Loss per share* was SEK 0.06 (loss: 0.21). First half year 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]

Xintela gets product patent in USA for chondrocyte-based products

Xintela today announces that the US Patent and Trademark Office (USPTO) has issued the company’s patent application on chondrocyte-based cell therapy products, with validity through 2039. Xintela’s US patent, US 11, 725,188, protects the development and commercialization of chondrocyte-based products that are quality assured using the cell surface markers integrin α10β1 and integrin α11β1. The […]

Xintela publishes positive preclinical results from XSTEM treatment of ARDS

Results from Xintela’s preclinical study with XSTEM® for the treatment of ARDS (Acute Respiratory Distress Syndrome) have been published in the journal Respiratory Research. The results show that XSTEM has a therapeutic effect and provides more stable blood circulation, reduced lung tissue damage and reduced blood clotting compared to placebo. Xintela has previously announced that […]

Xintela’s clinical study with XSTEM for knee osteoarthritis makes good progress

Xintela is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM® are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. The treatment of 16 patients […]